Discontinuation report STEGLUJAN
| Report ID | 133310 |
| Drug Identification Number | 02475901 |
| Brand name | STEGLUJAN |
| Common or Proper name | Ertugliflozin Sitagliptin tablets |
| Company Name | MERCK CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | ERTUGLIFLOZIN SITAGLIPTIN |
| Strength(s) | 5MG 100MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 30 |
| ATC code | A10BD |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2021-02-03 |
| Remaining supply date | 2021-02-03 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
| Company contact information | 1-800-567-2594 [email protected] |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2021-02-04 | French | Compare |
| v1 | 2021-02-04 | English | Compare |
Showing 1 to 2 of 2